Tsfg LLC Sells 168 Shares of The Clorox Company (NYSE:CLX)

Tsfg LLC reduced its position in The Clorox Company (NYSE:CLX) by 18.3% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 752 shares of the company’s stock after selling 168 shares during the period. Tsfg LLC’s holdings in Clorox were worth $115,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Northwest Financial Advisors purchased a new stake in Clorox during the 4th quarter worth about $29,000. GoalVest Advisory LLC bought a new position in shares of Clorox in the first quarter worth approximately $31,000. Core Wealth Advisors Inc. purchased a new stake in Clorox in the fourth quarter valued at approximately $29,000. Fortitude Family Office LLC bought a new stake in Clorox during the fourth quarter valued at approximately $29,000. Finally, First United Bank & Trust purchased a new position in Clorox in the 4th quarter worth approximately $31,000. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Stock Performance

Shares of NYSE CLX opened at $136.48 on Friday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 9.73. The Clorox Company has a 12-month low of $114.68 and a 12-month high of $169.14. The firm has a market capitalization of $16.95 billion, a price-to-earnings ratio of 70.72, a price-to-earnings-growth ratio of 2.19 and a beta of 0.39. The firm has a 50 day moving average of $136.95 and a 200 day moving average of $143.79.

Clorox (NYSE:CLX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.38. Clorox had a return on equity of 302.49% and a net margin of 3.33%. The business had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the previous year, the company posted $1.51 earnings per share. Clorox’s revenue for the quarter was down 5.3% on a year-over-year basis. On average, research analysts anticipate that The Clorox Company will post 5.91 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on CLX. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Clorox from $155.00 to $151.00 and set a “hold” rating on the stock in a research note on Wednesday, April 17th. Argus upgraded Clorox to a “hold” rating in a report on Tuesday, June 4th. Barclays dropped their target price on Clorox from $136.00 to $132.00 and set an “underweight” rating for the company in a report on Thursday, May 2nd. UBS Group decreased their price target on Clorox from $164.00 to $159.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 1st. Finally, DA Davidson reissued a “neutral” rating and set a $162.00 price objective on shares of Clorox in a research note on Wednesday, April 17th. Five research analysts have rated the stock with a sell rating and fourteen have assigned a hold rating to the company’s stock. Based on data from MarketBeat, Clorox has an average rating of “Hold” and a consensus target price of $145.33.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.